FDA
-
-
-
-
-
-
-
QIAGEN delivers solid Q4 2024 growth ahead of outlook
-
-
-
-
-
-
-
QIAGEN’s tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR framework
-
-
-
-
-
-
-
QIAGEN Expands QuantiFERON Portfolio in the Fight Against TB
-
-
-
-
-
-
-
QIAGEN receives U.S. FDA emergency use authorization for rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 antigen
-
-
-
-
-
-
-
QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer
-
-
-
-
-
-
-
Qiagen (QGEN) Granted FDA Emergency Use for NeuMoDx Multiplex Test to Quickly Identify Respiratory Viral Infection Consistent with COVID-19
-
-
-
-
-
-
-
QIAGEN Launches Portable Digital SARS-CoV-2 Antigen Test That Can Accurately Analyze Over 30 Samples Per Hour
-
326,827 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

